Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules - Trial NCT06279533
Access comprehensive clinical trial information for NCT06279533 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vigonvita Life Sciences
Timeline & Enrollment
Phase 1
Feb 01, 2024
Jul 01, 2024
Primary Outcome
Tmax,Cmax,T1/2,AUC0-t,AUC0-24h,AUC0-∞
Summary
This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of
 LV232 capsules after multiple ascending doses (hereinafter referred to as PK characteristics
 of multiple ascending doses study ) and food effect study (hereinafter referred to as FE
 study). A total of 48 subjects are planned to be enrolled. The two parts of the study can be
 carried out simultaneously, and there is no order requirement.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06279533
Non-Device Trial